223 related articles for article (PubMed ID: 21075272)
1. Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain.
Webster LR; Brewer R; Wang C; Sekora D; Johnson FK; Morris D; Stauffer J
J Pain Symptom Manage; 2010 Nov; 40(5):734-46. PubMed ID: 21075272
[TBL] [Abstract][Full Text] [Related]
2. Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain.
Katz N; Hale M; Morris D; Stauffer J
Postgrad Med; 2010 Jul; 122(4):112-28. PubMed ID: 20675975
[TBL] [Abstract][Full Text] [Related]
3. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers.
Johnson FK; Stark JG; Bieberdorf FA; Stauffer J
Clin Ther; 2010 Jun; 32(6):1149-64. PubMed ID: 20637968
[TBL] [Abstract][Full Text] [Related]
4. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety.
Katz N; Sun S; Johnson F; Stauffer J
J Pain; 2010 Apr; 11(4):303-11. PubMed ID: 19944650
[TBL] [Abstract][Full Text] [Related]
5. Morphine sulfate and naltrexone hydrochloride extended-release capsules: naltrexone release, pharmacodynamics, and tolerability.
Johnson F; Setnik B
Pain Physician; 2011; 14(4):391-406. PubMed ID: 21785483
[TBL] [Abstract][Full Text] [Related]
6. Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules.
Johnson FK; Ciric S; Boudriau S; Kisicki J; Stauffer J
J Clin Pharmacol; 2012 May; 52(5):747-56. PubMed ID: 21593282
[TBL] [Abstract][Full Text] [Related]
7. Opioid titration and conversion in patients receiving morphine sulfate and naltrexone hydrochloride extended release capsules.
Webster LR; Brewer R; Morris D; Cleveland JM; Setnik B
Postgrad Med; 2011 Sep; 123(5):155-64. PubMed ID: 21904098
[TBL] [Abstract][Full Text] [Related]
8. The relative bioavailability of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA®) and an extended release morphine sulfate capsule formulation (KADIAN®) in healthy adults under fasting conditions.
Johnson FK; Ciric S; Boudriau S; Kisicki JC; Stauffer J
Am J Ther; 2011 Jan; 18(1):2-8. PubMed ID: 20864883
[TBL] [Abstract][Full Text] [Related]
9. Morphine sulfate and naltrexone hydrochloride extended release capsules for the management of chronic, moderate-to-severe pain, while reducing morphine-induced subjective effects upon tampering by crushing.
Smith HS
Expert Opin Pharmacother; 2011 May; 12(7):1111-25. PubMed ID: 21470065
[TBL] [Abstract][Full Text] [Related]
10. Food effects on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules.
Johnson F; Ciric S; Boudriau S; Swearingen D; Stauffer J
Adv Ther; 2010 Nov; 27(11):846-58. PubMed ID: 20949341
[TBL] [Abstract][Full Text] [Related]
11. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients.
Setnik B; Roland CL; Goli V; Sommerville K; Webster L
J Opioid Manag; 2013; 9(2):139-50. PubMed ID: 23709323
[TBL] [Abstract][Full Text] [Related]
12. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study.
Stauffer J; Setnik B; Sokolowska M; Romach M; Johnson F; Sellers E
Clin Drug Investig; 2009; 29(12):777-90. PubMed ID: 19888784
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy comparison between morphine sulfate controlled-released tablet and morphine hydrochloride sustained-released tablet in treating cancer pain].
Yao WX; Zhou H; Wang LY; Wei Y; Liu XY
Ai Zheng; 2007 Dec; 26(12):1357-9. PubMed ID: 18076801
[TBL] [Abstract][Full Text] [Related]
14. A morphine/naltrexone combination (Embeda) for pain.
Med Lett Drugs Ther; 2010 Mar; 52(1334):22-3. PubMed ID: 20336033
[No Abstract] [Full Text] [Related]
15. Safety of EMBEda (morphine sulfate and naltrexone hydrochloride) extended-release capsules: review of postmarketing adverse events during the first year.
Badalamenti VC; Buckley JW; Smith ET
J Opioid Manag; 2012; 8(2):115-25. PubMed ID: 22616317
[TBL] [Abstract][Full Text] [Related]
16. Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users.
Webster LR; Johnson FK; Stauffer J; Setnik B; Ciric S
Drugs R D; 2011 Sep; 11(3):259-75. PubMed ID: 21902287
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain.
Arora S; Setnik B; Michael D; Hudson JD; Clemmer R; Meisner P; Pixton GC; Goli V; Sommerville KW
J Opioid Manag; 2014; 10(6):423-36. PubMed ID: 25531960
[TBL] [Abstract][Full Text] [Related]
18. KADIAN (morphine sulfate extended-release) capsules for treatment of chronic, moderate-to-severe, nonmalignant pain.
Ross EL; Hahn K
Int J Clin Pract; 2008 Mar; 62(3):471-9. PubMed ID: 18261077
[TBL] [Abstract][Full Text] [Related]
19. Safety profile of extended-release morphine sulfate with sequestered naltrexone hydrochloride in older patients: pooled analysis of three clinical trials.
Setnik B; Pixton GC; Webster LR
Curr Med Res Opin; 2016; 32(3):563-72. PubMed ID: 26695349
[TBL] [Abstract][Full Text] [Related]
20. Sustained-release morphine sulfate with sequestered naltrexone for moderate to severe pain: a new opioid analgesic formulation and beyond.
Ruan X
Expert Opin Pharmacother; 2011 May; 12(7):999-1001. PubMed ID: 21470064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
